Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.
Identifieur interne : 000068 ( Pmc/Corpus ); précédent : 000067; suivant : 000069Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.
Auteurs : G. Cheymol ; C. Bernheim ; J. Besson ; J. Dry ; R. PortetSource :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 1979.
Abstract
1 Thirty-three patients with no evidence of endocrine disease, hepatic or renal insufficiency or sleep disorders, were classified in groups 1 to 4 in order of increasing of percentage of ideal body weight (IBW) respectively: less than 90% of IBW, 90--120%, 120--180%, and greater than 180% of IBW. After oral administration of 200 mg butobarbitone, concentration of the intact drug was measured by gas liquid chromatographic assay in urine samples collected during 72 h and at three times in blood. 2 A highly significant negative relationship was found between the cumulative excretion of butobarbitone with urine and the logarithm of the percentage of IBW. In contrast for a given weight, excretion of the drug with urine was found to be weakly correlated with the diuresis. 3 The cumulative urinary elimination of butobarbitone was significantly different between the groups studied, except of the difference between the group 2 and 3 of the patients. No significant difference was found between the renal clearances of butobarbitone in the four groups of subjects. 4 We conclude that redistribution of butobarbitone into adipose tissues can explain the obtained results and that obesity modifies the pharmacokinetics of the drug.
Url:
PubMed: 34416
PubMed Central: 1429492
Links to Exploration step
PMC:1429492Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.</title>
<author><name sortKey="Cheymol, G" sort="Cheymol, G" uniqKey="Cheymol G" first="G" last="Cheymol">G. Cheymol</name>
</author>
<author><name sortKey="Bernheim, C" sort="Bernheim, C" uniqKey="Bernheim C" first="C" last="Bernheim">C. Bernheim</name>
</author>
<author><name sortKey="Besson, J" sort="Besson, J" uniqKey="Besson J" first="J" last="Besson">J. Besson</name>
</author>
<author><name sortKey="Dry, J" sort="Dry, J" uniqKey="Dry J" first="J" last="Dry">J. Dry</name>
</author>
<author><name sortKey="Portet, R" sort="Portet, R" uniqKey="Portet R" first="R" last="Portet">R. Portet</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">34416</idno>
<idno type="pmc">1429492</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429492</idno>
<idno type="RBID">PMC:1429492</idno>
<date when="1979">1979</date>
<idno type="wicri:Area/Pmc/Corpus">000068</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000068</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.</title>
<author><name sortKey="Cheymol, G" sort="Cheymol, G" uniqKey="Cheymol G" first="G" last="Cheymol">G. Cheymol</name>
</author>
<author><name sortKey="Bernheim, C" sort="Bernheim, C" uniqKey="Bernheim C" first="C" last="Bernheim">C. Bernheim</name>
</author>
<author><name sortKey="Besson, J" sort="Besson, J" uniqKey="Besson J" first="J" last="Besson">J. Besson</name>
</author>
<author><name sortKey="Dry, J" sort="Dry, J" uniqKey="Dry J" first="J" last="Dry">J. Dry</name>
</author>
<author><name sortKey="Portet, R" sort="Portet, R" uniqKey="Portet R" first="R" last="Portet">R. Portet</name>
</author>
</analytic>
<series><title level="j">British Journal of Clinical Pharmacology</title>
<idno type="ISSN">0306-5251</idno>
<idno type="eISSN">1365-2125</idno>
<imprint><date when="1979">1979</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>1 Thirty-three patients with no evidence of endocrine disease, hepatic or renal insufficiency or sleep disorders, were classified in groups 1 to 4 in order of increasing of percentage of ideal body weight (IBW) respectively: less than 90% of IBW, 90--120%, 120--180%, and greater than 180% of IBW. After oral administration of 200 mg butobarbitone, concentration of the intact drug was measured by gas liquid chromatographic assay in urine samples collected during 72 h and at three times in blood. 2 A highly significant negative relationship was found between the cumulative excretion of butobarbitone with urine and the logarithm of the percentage of IBW. In contrast for a given weight, excretion of the drug with urine was found to be weakly correlated with the diuresis. 3 The cumulative urinary elimination of butobarbitone was significantly different between the groups studied, except of the difference between the group 2 and 3 of the patients. No significant difference was found between the renal clearances of butobarbitone in the four groups of subjects. 4 We conclude that redistribution of butobarbitone into adipose tissues can explain the obtained results and that obesity modifies the pharmacokinetics of the drug.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id>
<journal-title>British Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0306-5251</issn>
<issn pub-type="epub">1365-2125</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">34416</article-id>
<article-id pub-id-type="pmc">1429492</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight.</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Cheymol</surname>
<given-names>G</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Bernheim</surname>
<given-names>C</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Besson</surname>
<given-names>J</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Dry</surname>
<given-names>J</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Portet</surname>
<given-names>R</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub"><month>3</month>
<year>1979</year>
</pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>303</fpage>
<lpage>309</lpage>
<abstract><p>1 Thirty-three patients with no evidence of endocrine disease, hepatic or renal insufficiency or sleep disorders, were classified in groups 1 to 4 in order of increasing of percentage of ideal body weight (IBW) respectively: less than 90% of IBW, 90--120%, 120--180%, and greater than 180% of IBW. After oral administration of 200 mg butobarbitone, concentration of the intact drug was measured by gas liquid chromatographic assay in urine samples collected during 72 h and at three times in blood. 2 A highly significant negative relationship was found between the cumulative excretion of butobarbitone with urine and the logarithm of the percentage of IBW. In contrast for a given weight, excretion of the drug with urine was found to be weakly correlated with the diuresis. 3 The cumulative urinary elimination of butobarbitone was significantly different between the groups studied, except of the difference between the group 2 and 3 of the patients. No significant difference was found between the renal clearances of butobarbitone in the four groups of subjects. 4 We conclude that redistribution of butobarbitone into adipose tissues can explain the obtained results and that obesity modifies the pharmacokinetics of the drug.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000068 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000068 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Psychologie |area= BernheimV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:1429492 |texte= Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:34416" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a BernheimV1
This area was generated with Dilib version V0.6.33. |